Electromed reports record FY2026 with robust homecare growth and leverage
Aug 25, 2026, 4:07 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The company delivered record revenue and profits, margin expansion (370+ bp lift vs FY2025), strong cash flow, no debt, and a stock buyback, all of which can support multiple expansion and a positive near-term price reaction. Historically, small-cap medical device names with solid top-line growth and leverage have seen 5–15% intraday moves on earnings beats; continued execution plus a clear bronchiectasis market opportunity could sustain upside into the next 1–2 quarters.
AI summary
What happened, with direct paths to the underlying reporting
Electromed posted record FY2026 results: revenue rose 15.3% to $73.8M, with operating income of $13.9M and net income of $11.3M ($1.30/share). Q4 2026 revenue was $19.4M, up 11.6% YoY. The company generated $9.7M of operating cash flow, repurchased $3.9M of stock, and ended the year with $20.5M cash, no debt, and a stronger direct homecare franchise targeting bronchiectasis patients via SmartVest.
Electromed reports FY2026 revenue at $73.8M, up 15.3% YoY (record).
Q4 FY2026 revenue $19.4M, up 11.6% YoY; FY2026 operating income $13.9M.
Net income $11.3M; diluted EPS $1.30; cash from operations $9.7M.
Strong direct homecare growth; stock repurchases $3.9M; cash $20.5M; no debt.
management targets bronchiectasis market; 800k patients could benefit from SmartVest.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
